Cat. No. 3422
Biological ActivityBombesin receptor antagonist that inhibits bombesin binding to rat brain with an IC50 value of 2 μM. Inhibits amylase release in vitro (IC50 = 4 μM) and attenuates bombesin-mediated suppression of food intake in vivo.
(Modifications: X = Glp, Phe-12 = D-Phe, Leu-14 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Flynn (1997) Bombesin receptor antagonists block the effects of exogenous bombesin but not of nutrients on food intake. Physiol.Behav. 62 791. PMID: 9284499.
Merali et al (1988) (d-Phe12) bombesin and substance P analogues function as central bombesin receptor antagonists. Synapse 2 282. PMID: 2463692.
Heinz-Erian et al (1987) [d-Phe12]bombesin analogues: a new class of bombesin receptor antagonists. Am.J.Physiol. 252 G439. PMID: 2435173.
If you know of a relevant reference for [D-Phe12,Leu14]-Bombesin please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses [D-Phe12,Leu14]-Bombesin from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: [D-Phe12,Leu14]-Bombesin, supplier, Bombesin, receptor, antagonists, GRP-Preferring, Receptors, BB1, BB2, BB3, Gastrin-Releasing, Peptide-Preferring, NMB-Preferring, Neuromedin, B-Preferring, Tocris Bioscience, Bombesin Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailableML 233
Non-peptide apelin receptor agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.